Reneo Pharmaceuticals, Inc. - Class A Common Stock (RPHM)

Reneo Pharmaceuticals is a biotechnology company focused on developing innovative therapies for rare mitochondrial diseases and other genetic disorders

The company is dedicated to advancing treatments that target the underlying mechanisms of these conditions to improve patient outcomes and quality of life. Reneo's research efforts are centered on harnessing the potential of small molecule drugs that can enhance mitochondrial function and metabolism, addressing significant unmet medical needs in the field of rare diseases. Through its cutting-edge scientific approach and commitment to patient-centered care, Reneo aims to make a meaningful impact in the lives of individuals affected by these challenging conditions.